Lenvima (Lenvatinib)

Lenvima (lenvatinib) is a kinase inhibitor that is indicated:
Differentiated Thyroid Cancer (DTC): For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma (RCC):

• In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
• In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
  Hepatocellular Carcinoma (HCC): For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
  Endometrial Carcinoma (EC): Along with pembrolizumab to treat patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Recommended Dosage:
Differentiated Thyroid Cancer (DTC): The recommended dosage of Lenvatinib is 24 mg orally once daily until disease progression or until unacceptable toxicity.

Renal Cell Carcinoma (RCC): The recommended dosage of Lenvatinib as a first-line treatment of patients with advanced RCC is 20 mg orally once daily along with pembrolizumab 200 mg administered as an intravenous (IV) infusion over 30 minutes every 3 weeks until there is evidence of disease progression or until unacceptable toxicity or up to 2 years. After completing 2 years of combination therapy, Lenvatinib may be administered as a single agent until there is evidence of disease progression or until unacceptable toxicity.
The recommended dosage of Lenvatinib for previously treated RCC is 18 mg along with 5 mg everolimus orally once daily until there is evidence of disease progression or until unacceptable toxicity.

Hepatocellular Carcinoma (HCC): The recommended dosage of Lenvatinib is 12 mg orally once daily for patients greater than or equal to 60 kg or 8 mg once daily for patients less than 60 kg. Take this medicine orally once daily until disease progression or until unacceptable toxicity.

Endometrial Carcinoma (EC): The recommended dosage of Lenvatinib is 20 mg orally once daily, along with pembrolizumab 200 mg administered as an intravenous (IV) infusion over 30 minutes every 3 weeks, until there is evidence of unacceptable toxicity or disease progression.

• Treatment with Lenvatinib 4 mg/10 mg capsules may be responsible for causing high blood pressure, which can become critical if not managed. Monitor blood pressure regularly, especially during the initial weeks of treatment. In case hypertension cannot be controlled with medicine, adjust or interrupt the dosage.
• Patients on this treatment may experience heart complications, including reduced heart function or heart failure. Symptoms such as swelling, shortness of breath, or fatigue need to be reported promptly. Regular heart monitoring is needed, mainly in those with pre-existing cardiac complications.
• Treatment with this medicine increases the risk of arterial clots, such as strokes or heart attacks. Use it with caution in individuals with a known history of such events. If symptoms like chest pain or sudden weakness occur, medical attention is urgently needed.
• Liver damage, including liver failure, may occur with Lenvatinib. Liver function must be checked before and during therapy. Signs such as dark urine, yellowing of skin or eyes, or abdominal pain may indicate critical liver complications.
  This medicine may impair kidney function or cause kidney failure, mainly in dehydrated patients. Monitoring kidney function during treatment is important. Patients should maintain good hydration and report any significant changes in urination patterns.
• This medicine can lead to protein in the urine, which may progress to a life-threatening kidney disorder. Conduct regular urine tests to detect early signs. In case of significant proteinuria, dose modification or treatment discontinuation may be needed.
• Diarrhea is a commonly reported side effect and may become serious. Patients should maintain hydration and let their doctor know if diarrhea persists or worsens. Supportive care and dose adjustment may be required for uncontrolled symptoms.
• This medicine may cause holes in the gastrointestinal tract or abnormal connections between organs (fistulas). These conditions are critical and potentially fatal. Patients with prior gastrointestinal complications must be closely monitored during therapy.
• This medicinal product may affect the heart’s electrical activity, potentially causing serious rhythm complications. ECG monitoring is required for those with known risk factors. Electrolyte levels like potassium and magnesium must be maintained within the normal range during treatment.
  Low calcium levels may be detected during treatment with Lenvatinib 4 mg/10 mg capsules, especially in those with thyroid cancer. Calcium and vitamin D supplementation might be necessary. Blood calcium levels must be monitored and corrected as required to prevent signs and symptoms like muscle cramps or confusion.
• Lenvatinib can be responsible for causing harm to an unborn baby. Do not use it during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 30 days after stopping the treatment. Let your doctor know in case pregnancy occurs.
• It is not known if this medicine passes into human breast milk, but it may harm the nursing infant. Avoid breastfeeding during treatment and for at least 7 days after the final dose. Discuss with your healthcare provider (HCP) before starting or stopping breastfeeding.

What documents are required to import LENVIMA to India?

LENVIMA (lenvatinib) Capsules can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is LENVIMA available in India?

LENVIMA (lenvatinib capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Lenvima in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

LENVIMA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of LENVIMA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Lenvima 4 mg/10 mg Capsule price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source LENVIMA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Lenvima®?

Lenvatinib is the Generic Name for the trade name drug Lenvima®.

What is the Manufacturer's Name of Lenvima®?

Lenvima® is manufactured by Eisai Pharmaceuticals Pvt Ltd.

What is the dosage and form of Lenvima® supplied?

Lenvima is supplied in an Capsule: 4 mg and 10 mg for oral administration.

What are the most common side effects of Lenvima® 4 mg/10 mg Capsule?

The most common side effects of Lenvima® are diarrhea, nausea, vomiting, constipation, decreased appetite, weight loss, mouth sores, changes in taste, Rash, redness, itching, or peeling of skin on the palms and soles of the feet, hair loss, Fatigue, headache, cough, hoarseness, difficulty sleeping, and fever.

How much does Lenvima® 4 mg/10 mg Capsule cost in India?

Prices of Lenvima Capsule may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Lenvima 4 mg/10 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Lenvima® 4 mg/10 mg Capsules be available in SAARC countries?

Apart from Gulf countries, Lenvima® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Lenvima® Capsule in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Lenvima® 4 mg/10 mg Capsule online in India?

Yes, one can buy Lenvima 4 mg/10 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Lenvima® Capsule through legal channels.

What are the storage conditions of Lenvima® 4 mg/10 mg Capsules?

Store Lenvatinib oral capsules at at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).